|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These stocks are not necessarily on their way to bankruptcy, but they do not exhibit the qualities that are precursors to improving fundamental performance.
Pacira must convince hospitals that its long-acting painkiller benefits patients and saves them money.
If the short-sellers can't knock these names down today, then there could be an underlying bid on these stocks that makes them attractive buys.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Nov. 5, 2010.
Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript
Cadence's pain drug was approved, but the stock sank because investors are more concerned about a financing overhang and the drug's commercial launch.
FDA approves drugs from Forest Labs and Avanir but rejects Biodel in what was a tough month overall for drug reviews.
Here's a list of November's potentially stock-moving biotech events
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Here is the updated list of drugs facing FDA approval decisions.
Cadence Pharmaceuticals Inc. Q2 2010 Earnings Call Transcript
Cadence Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Mannkind needs to clarify the cause and extent of the FDA's decision to delay approval of its inhaled insulin device.
Cadence Pharma says FDA expects to make a decision on its IV painkiler by mid-February
A quick and dirty guide to upcoming FDA approval dates for biotech drugs.
Cadence requests FDA approval of Acetavance, an IV form of acetaminophen for pain and fever
Dendreon raised $230 million in the year's second-largest biotech follow-on stock offering.
Cadence Pharmaceuticals' 4th-quarter loss narrows slightly on lower expenses
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.